MA49607A1 - Anticorps monoclonal pour il-5ra - Google Patents

Anticorps monoclonal pour il-5ra

Info

Publication number
MA49607A1
MA49607A1 MA49607A MA49607A MA49607A1 MA 49607 A1 MA49607 A1 MA 49607A1 MA 49607 A MA49607 A MA 49607A MA 49607 A MA49607 A MA 49607A MA 49607 A1 MA49607 A1 MA 49607A1
Authority
MA
Morocco
Prior art keywords
monoclonal antibody
antibodies
methods
relates
dnas
Prior art date
Application number
MA49607A
Other languages
English (en)
Other versions
MA49607B2 (fr
Inventor
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Ekaterina Vladimirovna Sofronova
Aleksei Konstantinovich Misorin
Aleksandr Nikolaevich Doronin
Timofey Aleksandrovich Nemankin
Aleksandra Aleksandrovna Sozonova
Galina Stepanovna Zhirivskala
Sergey Aleksandrovich Legotsky
Anna Konstantinovna Vladimirova
Alina Valerevna Beliasnikova
Mariia Aleksandrovna Shchemeleva
Pavel Andreevich Iakovlev
Elena Andreevna Krendeleva
Natalia Evgenevna Pestova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA49607A1 publication Critical patent/MA49607A1/fr
Publication of MA49607B2 publication Critical patent/MA49607B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne le domaine de la biotechnologie et propose des anticorps qui se lient spécifiquement à il-5ra. L'invention concerne des adn qui codent pour lesdits anticorps, qui correspondent aux vecteurs d'expression, et des procédés de production ainsi que des méthodes de traitement utilisant ces anticorps.
MA49607A 2017-10-03 2018-10-02 ANTICORPS MONOCLONAL POUR IL-5Rα MA49607B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017134413A RU2698048C2 (ru) 2017-10-03 2017-10-03 МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
PCT/RU2018/050118 WO2019070164A1 (fr) 2017-10-03 2018-10-02 ANTICORPS MONOCLONAL POUR IL-5Rα

Publications (2)

Publication Number Publication Date
MA49607A1 true MA49607A1 (fr) 2021-03-31
MA49607B2 MA49607B2 (fr) 2024-11-29

Family

ID=65994565

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49607A MA49607B2 (fr) 2017-10-03 2018-10-02 ANTICORPS MONOCLONAL POUR IL-5Rα

Country Status (23)

Country Link
US (1) US12173075B2 (fr)
EP (1) EP3693388A4 (fr)
JP (1) JP7275117B2 (fr)
KR (1) KR102749809B1 (fr)
CN (1) CN111788223B (fr)
AR (1) AR113343A1 (fr)
AU (1) AU2018346116B2 (fr)
BR (1) BR112020006795A2 (fr)
CA (1) CA3078467A1 (fr)
CL (1) CL2020000920A1 (fr)
CO (1) CO2020004200A2 (fr)
EA (1) EA202090864A1 (fr)
EC (1) ECSP20024551A (fr)
JO (1) JOP20200106A1 (fr)
MA (1) MA49607B2 (fr)
MX (1) MX2020004026A (fr)
PE (1) PE20210466A1 (fr)
PH (1) PH12020550218A1 (fr)
RU (1) RU2698048C2 (fr)
TW (1) TWI758547B (fr)
UY (1) UY37914A (fr)
WO (1) WO2019070164A1 (fr)
ZA (1) ZA202002044B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR102697770B1 (ko) * 2020-09-14 2024-08-23 아주대학교산학협력단 인간 IL-5Rα에 결합하는 항체 및 이의 용도
JP2023553641A (ja) * 2020-12-17 2023-12-25 アストラゼネカ アクチボラグ 抗ｉｌ５ｒ抗体製剤
US20240317689A1 (en) * 2021-08-26 2024-09-26 Neushen Therapeutics (Shanghai) Co., Ltd Potassium channel modulator, composition and application

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (fr) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Proteine cd2 soluble a deux domaines
CA2046909A1 (fr) 1989-03-21 1990-09-22 Mark D. Howell Vaccination et methodes d'immunisation contre les maladies resultant de reactions pathogenes provoquees par des populations de lymphocytes t
EP0739904A1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Réactifs bispécifiques pour le traitement du SIDA
JP3072330B2 (ja) 1989-07-19 2000-07-31 ジ・イミューン・レスポンス・コーポレーション 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
FR2783326B1 (fr) 1998-09-10 2000-12-01 Immunotech Sa Procede de detection ou de quantification des basophiles et des eosinophiles
EP2275540B1 (fr) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
WO2001060405A1 (fr) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Inducteur de l'apoptose specifique a l'eosinophilie
MXPA03002278A (es) 2000-09-14 2004-12-03 Beth Israel Hospital Modulacion de respuestas de la celula t mediadas por il-2 e il-15.
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
PT3072525T (pt) * 2007-05-14 2018-04-20 Astrazeneca Ab Métodos para reduzir os níveis de basófilos
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MX2015007446A (es) 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
CA2918105C (fr) * 2013-08-12 2023-02-28 Medimmune, Llc Procedes pour reduire des taux d'exacerbation d'asthme a l'aide de benralizumab
WO2015058861A1 (fr) * 2013-10-25 2015-04-30 Numab Ag Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies
US20170073415A1 (en) 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension

Also Published As

Publication number Publication date
NZ763877A (en) 2025-05-02
EA202090864A1 (ru) 2020-06-29
MX2020004026A (es) 2020-08-13
ECSP20024551A (es) 2020-06-30
PH12020550218A1 (en) 2021-02-15
JOP20200106A1 (ar) 2020-05-06
BR112020006795A2 (pt) 2020-10-06
KR20200058537A (ko) 2020-05-27
RU2698048C2 (ru) 2019-08-21
KR102749809B1 (ko) 2025-01-03
UY37914A (es) 2019-04-30
CL2020000920A1 (es) 2020-10-16
TWI758547B (zh) 2022-03-21
ZA202002044B (en) 2022-08-31
RU2017134413A (ru) 2019-04-03
US20200291121A1 (en) 2020-09-17
JP2021501568A (ja) 2021-01-21
CN111788223B (zh) 2024-08-30
AU2018346116A1 (en) 2020-05-14
AR113343A1 (es) 2020-04-22
RU2017134413A3 (fr) 2019-04-03
CA3078467A1 (fr) 2019-04-11
CN111788223A (zh) 2020-10-16
PE20210466A1 (es) 2021-03-08
TW201922789A (zh) 2019-06-16
US12173075B2 (en) 2024-12-24
CO2020004200A2 (es) 2020-04-24
MA49607B2 (fr) 2024-11-29
EP3693388A1 (fr) 2020-08-12
WO2019070164A1 (fr) 2019-04-11
JP7275117B2 (ja) 2023-05-17
AU2018346116B2 (en) 2025-10-09
EP3693388A4 (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
MA47221A1 (fr) Anticorps monoclonal à pd-l1
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
MA49034B1 (fr) Anticorps anti-lag3
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
MA41596A (fr) Anticorps anti-tau et leurs utilisations
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MA49607B2 (fr) ANTICORPS MONOCLONAL POUR IL-5Rα
MA38161A1 (fr) Anticorps anti-bmp-6
MA53186B2 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
MA43600B2 (fr) Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire
MA45831B1 (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
GEP20247700B (en) Antibody variants
EA201891196A1 (ru) Cgrp-антитела и их применение
EA202092981A1 (ru) Антитела к l1cam и их применение
EA202090929A1 (ru) Антитела, активируемые антитела, биспецифические антитела и биспецифические активируемые антитела и способы их применения
MA39300A1 (fr) Anticorps bispécifiques anti-il-13/il-17 et leurs utilisations
MA41930A1 (fr) Composition pour traitement de la maladie du bayoud
MA41666B1 (fr) Anticorps anti-ox40 et leurs utilisations
MA41826B1 (fr) Anticorps anti-icos